Review



mpc  (Mesoblast Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Mesoblast Ltd mpc
    Mpc, supplied by Mesoblast Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/mpc/pmc13176351-36-4-5
    Average 86 stars, based on 1 article reviews
    mpc - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Clinical translational research on stem cell products: prospects and challenges
    Article Snippet: Mesenchymal precursor cells , MPC (Mesoblast Ltd) , Bone repair , Australia , 2010.



    Similar Products

    mpc  (ATCC)
    96
    ATCC mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/pmc13266118-123-0-5
    Average 96 stars, based on 1 article reviews
    mpc - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    e6 1  (ATCC)
    93
    ATCC e6 1
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    E6 1, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC+11+OUAr/pm42827183-255-3-4
    Average 93 stars, based on 1 article reviews
    e6 1 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    mpc 11 mouse tumors  (ATCC)
    96
    ATCC mpc 11 mouse tumors
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc 11 Mouse Tumors, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/us12655222-489-17-40
    Average 96 stars, based on 1 article reviews
    mpc 11 mouse tumors - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    mpc11  (ATCC)
    96
    ATCC mpc11
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc11, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/pmc13148948-199-36-37
    Average 96 stars, based on 1 article reviews
    mpc11 - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    linear multi point constraint mpc equations  (Abaqus Inc)
    86
    Abaqus Inc linear multi point constraint mpc equations
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Linear Multi Point Constraint Mpc Equations, supplied by Abaqus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/constraint+mpc+multi+point+subroutine/pm42151261-204-31-29
    Average 86 stars, based on 1 article reviews
    linear multi point constraint mpc equations - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    mpc  (Mesoblast Ltd)
    86
    Mesoblast Ltd mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc, supplied by Mesoblast Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/mpc/pmc13176351-36-4-5
    Average 86 stars, based on 1 article reviews
    mpc - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    milk protein concentrate mpc  (Agropur Inc)
    86
    Agropur Inc milk protein concentrate mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Milk Protein Concentrate Mpc, supplied by Agropur Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/concentrate+milk+mpc+protein/pm42075077-41-0-12
    Average 86 stars, based on 1 article reviews
    milk protein concentrate mpc - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

    Journal: Molecular Therapy Oncology

    Article Title: Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition

    doi: 10.1016/j.omton.2026.201226

    Figure Lengend Snippet: Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

    Article Snippet: MPC-11 murine plasmacytoma cells (CCL-167, American Type Culture Collection, Manassas, VA) were maintained in DMEM supplemented with 10% fetal bovine serum.

    Techniques: Clinical Proteomics, Saline